Fulcrum Therapeutics Inc (FULC)

Fulcrum Therapeutics Inc Borsa (FULC) Ultime notizie

Fulcrum Therapeutics Inc: Weathering Stock Market Storms with 481.04M Market Cap - The InvestChronicle

The InvestChronicle

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Average Rating of "Buy" by Brokerages - MarketBeat

MarketBeat

Here's Why Fulcrum Therapeutics, Inc. (FULC) is Poised for a Turnaround After Losing 32.6% in 4 Weeks - Yahoo New Zealand News

Yahoo New Zealand News

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Average Rating of “Buy” from Brokerages - Defense World

Defense World

Understanding the Risks of Investing in Fulcrum Therapeutics Inc (FULC) – Knox Daily - Knox Daily

Knox Daily

What Does The Future Hold For Fulcrum Therapeutics, Inc. (NASDAQ:FULC)? These Analysts Have Been Cutting Their ... - Yahoo News UK

Yahoo News UK

Learn to Evaluate (FULC) using the Charts - Stock Traders Daily

Stock Traders Daily

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) to Post FY2024 Earnings of ($0.78) Per Share, Cantor Fitzgerald Forecasts - Defense World

Defense World

Financial Survey: Fulcrum Therapeutics (NASDAQ:FULC) & Cytokinetics (NASDAQ:CYTK) - Defense World

Defense World

Research Analysts Set Expectations for Fulcrum Therapeutics, Inc.'s FY2024 Earnings (NASDAQ:FULC) - MarketBeat

MarketBeat

Fulcrum Therapeutics (NASDAQ:FULC) Readies Phase 3 Candidate with Blockbuster Potential - Nasdaq

Nasdaq

Understanding the Risks of Investing in Fulcrum Therapeutics Inc (FULC) – Knox Daily - Knox Daily

Knox Daily

Financial Health Report: Fulcrum Therapeutics Inc (FULC)'s Ratios Tell a Tale – DWinneX - The Dwinnex

The Dwinnex

It would be worthwhile to take a closer look at Fulcrum Therapeutics Inc (FULC) – US Post News - US Post News

US Post News

Fulcrum Therapeutics Sees Unusually Large Options Volume (NASDAQ:FULC) - Defense World

Defense World

Stock Traders Purchase High Volume of Call Options on Fulcrum Therapeutics (NASDAQ:FULC) - MarketBeat

MarketBeat

Fulcrum Therapeutics, Inc. (FULC) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Singapore News

Yahoo Singapore News

Cantor Fitzgerald eyes Fulcrum Therapeutics stock, anticipates positive Phase 3 data - Investing.com Canada

Investing.com Canada

Fulcrum Therapeutics, Inc. (FULC) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Lifestyle Australia

Yahoo Lifestyle Australia

Fulcrum Therapeutics (NASDAQ:FULC) Earns Overweight Rating from Analysts at Cantor Fitzgerald - MarketBeat

MarketBeat

Cantor Fitzgerald eyes Fulcrum Therapeutics stock, anticipates positive Phase 3 data - Investing.com UK

Investing.com UK

Fulcrum Therapeutics Inc [FULC] stock for 1831 USD was sold by Tourangeau Greg – Knox Daily - Knox Daily

Knox Daily

Fulcrum Therapeutics, Inc. (FULC) Stock Jumps 5.7%: Will It Continue to Soar? - Yahoo Movies UK

Yahoo Movies UK

FULC’s Stock Market Adventure: 15.48% YTD Growth Amidst Volatility - The InvestChronicle

The InvestChronicle

The Zacks Analyst Blog Highlights Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers - Yahoo Finance

Yahoo Finance

Fulcrum Therapeutics' Collaboration and License Agreement with Sanofi – Global Legal Chronicle - Global Legal Chronicle

Global Legal Chronicle

Q2 2024 EPS Estimates for Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Boosted by Leerink Partnrs - Defense World

Defense World

Fulcrum Therapeutics' Collaboration and License Agreement with Sanofi – Global Legal Chronicle - Global Legal Chronicle

Global Legal Chronicle

Research Analysts Issue Forecasts for Fulcrum Therapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:FULC) - MarketBeat

MarketBeat

Biotech Stock Roundup: NVAX, FULC Up on Deals With SNY, Updates From MRNA, BMY

Zacks Investment Research

Fulcrum Therapeutics' (FULC) “Buy” Rating Reaffirmed at HC Wainwright - Defense World

Defense World

HC Wainwright Research Analysts Decrease Earnings Estimates for Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World

Defense World

HC Wainwright Research Analysts Decrease Earnings Estimates for Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World

Defense World

(FULC) Trading Advice - Stock Traders Daily

Stock Traders Daily

Oppenheimer Lowers Fulcrum Therapeutics (NASDAQ:FULC) Price Target to $14.00 - Defense World

Defense World

Prepare Yourself for Liftoff: Fulcrum Therapeutics Inc (FULC) – Sete News - SETE News

SETE News

HC Wainwright Equities Analysts Decrease Earnings Estimates for Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - MarketBeat

MarketBeat

Wall Street Analysts See a 69.15% Upside in Fulcrum Therapeutics (FULC): Can the Stock Really Move This High? - Yahoo Finance

Yahoo Finance

Fulcrum upgraded by Goldman Sachs ahead of Phase 3 data - MSN

MSN

Wall Street Analysts See a 69.15% Upside in Fulcrum Therapeutics (FULC): Can the Stock Really Move This High? - Yahoo Finance

Yahoo Finance

Fulcrum Therapeutics stock rating reiterated amid Sanofi deal - Investing.com South Africa

Investing.com South Africa

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Short Interest Up 18.6% in April - MarketBeat

MarketBeat

HC Wainwright Reiterates Buy Rating for Fulcrum Therapeutics (NASDAQ:FULC) - MarketBeat

MarketBeat

Fulcrum Therapeutics (NASDAQ:FULC) Given Buy Rating at HC Wainwright - MarketBeat

MarketBeat

Fulcrum Therapeutics (NASDAQ:FULC) Given New $14.00 Price Target at Oppenheimer - MarketBeat

MarketBeat

Fulcrum Therapeutics stock rating reiterated amid Sanofi deal By Investing.com - Investing.com UK

Investing.com UK

Fulcrum Therapeutics First Quarter 2024 Earnings: US$0.43 loss per share (vs US$0.41 loss in 1Q 2023) - Simply Wall St

Simply Wall St

Will Fulcrum Therapeutics (NASDAQ:FULC) Spend Its Cash Wisely? - Yahoo Finance

Yahoo Finance

Goldman Sachs Upgrades Fulcrum Therapeutics (FULC) - MSN

MSN

Fulcrum Therapeutics Enters into Agreement with Sanofi - European Pharmaceutical Manufacturer

European Pharmaceutical Manufacturer